Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + inactivated poliovirus vaccine
- Development stage
- Discontinued
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
DT Polio is an adsorbed combination vaccine developed and manufactured by Sanofi Pasteur MSD (and later managed by Sanofi Pasteur) for the prevention of diphtheria, tetanus, and poliomyelitis. It is formulated with a standard (full) dose of diphtheria toxoid, tetanus toxoid, and inactivated poliovirus types 1, 2, and 3 (DT-IPV), adsorbed on aluminum hydroxide. Primarily used in France as a booster dose in children at 6 years of age, DT Polio was compared in a Phase 3 clinical trial against REVAXIS (a low-dose diphtheria formulation). Due to recurrent shortages and an increase in allergic reactions, DT Polio was suspended and permanently discontinued in France in 2008, with REVAXIS and other multi-valent vaccines serving as alternatives.
- Brand names
- DT PolioD.T. Polio Mérieux
- Other names
- DT-IPVdiphtheria-tetanus-poliomyelitis vaccinediphtheria, tetanus, and poliomyelitis vaccine
02
Targets
WPV3 (Poliovirus type 3 capsid protein)Poliovirus type 1 capsid proteinTT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + inactivated poliovirus vaccine.